BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 27062924)

  • 1. Steroid Receptors Reprogram FoxA1 Occupancy through Dynamic Chromatin Transitions.
    Swinstead EE; Miranda TB; Paakinaho V; Baek S; Goldstein I; Hawkins M; Karpova TS; Ball D; Mazza D; Lavis LD; Grimm JB; Morisaki T; Grøntved L; Presman DM; Hager GL
    Cell; 2016 Apr; 165(3):593-605. PubMed ID: 27062924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FoxA1 binding directs chromatin structure and the functional response of a glucocorticoid receptor-regulated promoter.
    Belikov S; Astrand C; Wrange O
    Mol Cell Biol; 2009 Oct; 29(20):5413-25. PubMed ID: 19687299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analyses of an epigenetic switch involved in the activation of pioneer factor FOXA1 leading to the prognostic value of estrogen receptor and FOXA1 co-expression in breast cancer.
    Jing X; Liang H; Hao C; Hongxia L; Cui X
    Aging (Albany NY); 2019 Sep; 11(18):7442-7456. PubMed ID: 31562808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXA1 is a key determinant of estrogen receptor function and endocrine response.
    Hurtado A; Holmes KA; Ross-Innes CS; Schmidt D; Carroll JS
    Nat Genet; 2011 Jan; 43(1):27-33. PubMed ID: 21151129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromatin accessibility and pioneer factor FOXA1 restrict glucocorticoid receptor action in prostate cancer.
    Helminen L; Huttunen J; Tulonen M; Aaltonen N; Niskanen EA; Palvimo JJ; Paakinaho V
    Nucleic Acids Res; 2024 Jan; 52(2):625-642. PubMed ID: 38015476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Druggable FOXA1-Glucocorticoid Receptor Transcriptional Axis Drives Tumor Growth in a Subset of Non-Small Cell Lung Cancer.
    Dorso M; Patel PT; Pankov A; Boyer JA; Soni RK; Del Priore IS; Hayatt O; Kulick A; Hagen CJ; de Stanchina E; Junttila MR; Daemen A; Friedman LS; Hendrickson RC; Chandarlapaty S
    Cancer Res Commun; 2023 Sep; 3(9):1788-1799. PubMed ID: 37691854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXA1 Reprogramming Dictates Retinoid X Receptor Response in ESR1-Mutant Breast Cancer.
    Wu Y; Li Z; Wedn AM; Casey AN; Brown D; Rao SV; Omarjee S; Hooda J; Carroll JS; Gertz J; Atkinson JM; Lee AV; Oesterreich S
    Mol Cancer Res; 2023 Jun; 21(6):591-604. PubMed ID: 36930833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.
    Arruabarrena-Aristorena A; Maag JLV; Kittane S; Cai Y; Karthaus WR; Ladewig E; Park J; Kannan S; Ferrando L; Cocco E; Ho SY; Tan DS; Sallaku M; Wu F; Acevedo B; Selenica P; Ross DS; Witkin M; Sawyers CL; Reis-Filho JS; Verma CS; Jauch R; Koche R; Baselga J; Razavi P; Toska E; Scaltriti M
    Cancer Cell; 2020 Oct; 38(4):534-550.e9. PubMed ID: 32888433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Genomic Analysis Reveals that the Pioneering Function of FOXA1 Is Independent of Hormonal Signaling.
    Glont SE; Chernukhin I; Carroll JS
    Cell Rep; 2019 Mar; 26(10):2558-2565.e3. PubMed ID: 30840881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FoxA1 and glucocorticoid receptor crosstalk via histone H4K16 acetylation at a hormone regulated enhancer.
    Belikov S; Holmqvist PH; Astrand C; Wrange Ö
    Exp Cell Res; 2012 Jan; 318(1):61-74. PubMed ID: 22001115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different chromatin-scanning modes lead to targeting of compacted chromatin by pioneer factors FOXA1 and SOX2.
    Lerner J; Katznelson A; Zhang J; Zaret KS
    Cell Rep; 2023 Jul; 42(7):112748. PubMed ID: 37405916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonlinear relationship between chromatin accessibility and estradiol-regulated gene expression.
    Chen D; Parker TM; Bhat-Nakshatri P; Chu X; Liu Y; Wang Y; Nakshatri H
    Oncogene; 2021 Feb; 40(7):1332-1346. PubMed ID: 33420376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine response.
    Fu X; Huang C; Schiff R
    Breast Cancer Res; 2011 Apr; 13(2):307. PubMed ID: 21575280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ER regulates an evolutionarily conserved apoptosis pathway.
    Liu Z; Chen S
    Biochem Biophys Res Commun; 2010 Sep; 400(1):34-8. PubMed ID: 20691160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FoxA1 binding to the MMTV LTR modulates chromatin structure and transcription.
    Holmqvist PH; Belikov S; Zaret KS; Wrange O
    Exp Cell Res; 2005 Apr; 304(2):593-603. PubMed ID: 15748903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer-specific mutation of GATA3 disrupts the transcriptional regulatory network governed by Estrogen Receptor alpha, FOXA1 and GATA3.
    Takaku M; Grimm SA; De Kumar B; Bennett BD; Wade PA
    Nucleic Acids Res; 2020 May; 48(9):4756-4768. PubMed ID: 32232341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of lineage-specific epigenetic regulators FOXA1 and GRHL2 through chromatin accessibility profiling in breast cancer cell lines.
    Yang L; Kumegawa K; Saeki S; Nakadai T; Maruyama R
    Cancer Gene Ther; 2024 May; 31(5):736-745. PubMed ID: 38429368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer.
    Sahu B; Laakso M; Ovaska K; Mirtti T; Lundin J; Rannikko A; Sankila A; Turunen JP; Lundin M; Konsti J; Vesterinen T; Nordling S; Kallioniemi O; Hautaniemi S; Jänne OA
    EMBO J; 2011 Sep; 30(19):3962-76. PubMed ID: 21915096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOXA1 is an independent prognostic marker for ER-positive breast cancer.
    Mehta RJ; Jain RK; Leung S; Choo J; Nielsen T; Huntsman D; Nakshatri H; Badve S
    Breast Cancer Res Treat; 2012 Feb; 131(3):881-90. PubMed ID: 21503684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer.
    Xu G; Chhangawala S; Cocco E; Razavi P; Cai Y; Otto JE; Ferrando L; Selenica P; Ladewig E; Chan C; Da Cruz Paula A; Witkin M; Cheng Y; Park J; Serna-Tamayo C; Zhao H; Wu F; Sallaku M; Qu X; Zhao A; Collings CK; D'Avino AR; Jhaveri K; Koche R; Levine RL; Reis-Filho JS; Kadoch C; Scaltriti M; Leslie CS; Baselga J; Toska E
    Nat Genet; 2020 Feb; 52(2):198-207. PubMed ID: 31932695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.